

MAP Pharmaceuticals, Inc.  
Form 4  
June 29, 2009

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
FirstMark Capital, L.L.C.

2. Issuer Name and Ticker or Trading Symbol  
MAP Pharmaceuticals, Inc. [MAPP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
1221 SIXTH AVENUE  
  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
06/26/2009

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  Other (specify below)  
See Footnote 1

NEW YORK, NY 10020

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V Amount or (D) Price   |   |  |   |
| Common Stock                    | 06/26/2009                           |  | S                              | 466 <sup>(2)</sup> D \$ 11.28                                     | 2,124,633 <sup>(2)</sup>  | I <sup>(2)</sup>   | Investment Advisor <sup>(1)</sup>                     |
| Common Stock                    | 06/26/2009                           |  | S                              | 1,075 <sup>(2)</sup> D \$ 11.29                                   | 2,123,558 <sup>(2)</sup>  | I <sup>(2)</sup>   | Investment Advisor <sup>(1)</sup>                     |
| Common Stock                    | 06/26/2009                           |  | S                              | 2,000 <sup>(2)</sup> D \$ 11.3                                    | 2,121,558 <sup>(2)</sup>  | I <sup>(2)</sup>   | Investment Advisor <sup>(1)</sup>                     |
| Common Stock                    | 06/26/2009                           |  | S                              | 100 <sup>(2)</sup> D \$ 11.3075                                   | 2,121,458 <sup>(2)</sup>  | I <sup>(2)</sup>   | Investment Advisor <sup>(1)</sup>                     |
| Common Stock                    | 06/26/2009                           |  | S                              | 1,300 <sup>(2)</sup> D \$ 11.31                                   | 2,120,158 <sup>(2)</sup>  | I <sup>(2)</sup>   | Investment Advisor <sup>(1)</sup>                     |

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

|              |            |   |                            |   |            |                      |              |                               |
|--------------|------------|---|----------------------------|---|------------|----------------------|--------------|-------------------------------|
| Common Stock | 06/26/2009 | S | <u>1,700</u><br><u>(2)</u> | D | \$ 11.32   | 2,118,458 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>400</u><br><u>(2)</u>   | D | \$ 11.325  | 2,118,058 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>400</u><br><u>(2)</u>   | D | \$ 11.327  | 2,117,658 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>100</u><br><u>(2)</u>   | D | \$ 11.3275 | 2,117,558 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>2,020</u><br><u>(2)</u> | D | \$ 11.33   | 2,115,538 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>2,656</u><br><u>(2)</u> | D | \$ 11.34   | 2,112,882 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>5,800</u><br><u>(2)</u> | D | \$ 11.35   | 2,107,082 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>76</u><br><u>(2)</u>    | D | \$ 11.355  | 2,107,006 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>4,700</u><br><u>(2)</u> | D | \$ 11.36   | 2,102,306 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>200</u><br><u>(2)</u>   | D | \$ 11.3625 | 2,102,106 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>100</u><br><u>(2)</u>   | D | \$ 11.365  | 2,102,006 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>200</u><br><u>(2)</u>   | D | \$ 11.3675 | 2,101,806 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>1,860</u><br><u>(2)</u> | D | \$ 11.37   | 2,099,946 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>100</u><br><u>(2)</u>   | D | \$ 11.375  | 2,099,846 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>3,524</u><br><u>(2)</u> | D | \$ 11.38   | 2,096,322 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>5,300</u><br><u>(2)</u> | D | \$ 11.39   | 2,091,022 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>100</u><br><u>(2)</u>   | D | \$ 11.3925 | 2,090,922 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>1,500</u><br><u>(2)</u> | D | \$ 11.395  | 2,089,422 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>200</u><br><u>(2)</u>   | D | \$ 11.3975 | 2,089,222 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
| Common Stock | 06/26/2009 | S | <u>4,600</u><br><u>(2)</u> | D | \$ 11.4    | 2,084,622 <u>(2)</u> | I <u>(2)</u> | Investment Advisor <u>(1)</u> |
|              | 06/26/2009 | S | <u>600</u><br><u>(2)</u>   | D | \$ 11.405  | 2,084,022 <u>(2)</u> | I <u>(2)</u> |                               |

Edgar Filing: MAP Pharmaceuticals, Inc. - Form 4

|              |            |  |   |                      |   |           |                          |                  |                                   |
|--------------|------------|--|---|----------------------|---|-----------|--------------------------|------------------|-----------------------------------|
| Common Stock |            |  |   |                      |   |           |                          |                  | Investment Advisor <sup>(1)</sup> |
| Common Stock | 06/26/2009 |  | S | 1,300 <sup>(2)</sup> | D | \$ 11.41  | 2,082,722 <sup>(2)</sup> | I <sup>(2)</sup> | Investment Advisor <sup>(1)</sup> |
| Common Stock | 06/26/2009 |  | S | 1,000 <sup>(2)</sup> | D | \$ 11.415 | 2,081,722 <sup>(2)</sup> | I <sup>(2)</sup> | Investment Advisor <sup>(1)</sup> |
| Common Stock | 06/26/2009 |  | S | 200 <sup>(2)</sup>   | D | \$ 11.42  | 2,081,522 <sup>(2)</sup> | I <sup>(2)</sup> | Investment Advisor <sup>(1)</sup> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares   |

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

FirstMark Capital, L.L.C.  
1221 SIXTH AVENUE  
NEW YORK, NY 10020

See Footnote 1

## Signatures

/s/ Brian Kempner, Chief Operating Officer & General Counsel

06/29/2009

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- FirstMark Capital, L.L.C., a Delaware limited liability company ("FirstMark"), is an investment advisor acting on behalf of its clients' accounts. FirstMark disclaims any obligation to file this report, and this report shall not be deemed an admission that FirstMark is subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with respect to the Issuer of such securities.
- (1) FirstMark disclaims any obligation to file this report, and this report shall not be deemed an admission that FirstMark is subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), with respect to the Issuer of such securities.
  - (2) FirstMark disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that FirstMark is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of such securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.